Impact of left atrial diameter on outcome in patients undergoing edge-to-edge mitral valve repair: results from the German TRAnscatheter Mitral valve Interventions registry (TRAMI)

C. Iliadis¹, S. Baldus¹, D. Kalbacher², P. Boekstegers³, W. Schillinger⁴, T. Ouarrak⁵, R. Zahn⁶, C. Butter⁷, C.S. Zuern⁸, R.S. Von Bardeleben⁹, J. Senges⁵, R. Bekeredjian¹⁰, H. Eggebrecht¹¹, R. Pfister¹

¹ Cologne University Hospital - Heart Center, Department III of Internal Medicine, Heart Center, University of Cologne, Cologne Germany, Cologne, Germany; ²University Heart Center Hamburg, University Heart Center Eppendorf, Hamburg, Department of Cardiology, Hamburg, Germany;
³ Helios Hospital Siegburg-Bonn, Helios Clinic Siegburg, Department of Cardiology and Angiology, Siegburg, Germany; ⁴ Georg-August University, Georg-August-University Göttingen, Heart Center, Department of Cardiology, Goettingen, Germany; ⁵ IHF Gmbh - Institut Fuer
Herzinfarktforschung, "Stiftung Institut für Herzinfarktforschung", Ludwigshafen, Foundation Institute for Myocardial Infa, Ludwigshafen, Germany; ⁶ Klinikum Ludwigshafen, Ludwigshafen Clinic, Department of Medicine B, Ludwigshafen, Germany; ⁷ Brandenburg Heart Center, Cardiology Department, Heart Center Brandenburg Bernau, Bernau bei Berlin, Germany; ⁸ University Hospital of Tuebingen, University Clinic Tübingen, Department of Cardiology, Tuebingen, Germany; ⁹ University Medical Center Mainz, University Medicine Mainz, Center for Cardiology, Heart Valve Center, Mainz, Germany; ¹⁰ Robert Bosch Hospital, Robert-Bosch-Hospital Stuttgart, Cardiology Department, Stuttgart, Germany; ¹¹ CardioVascular Center Bethanien (CCB), Cardiology Centrum Bethanien – CCB, Frankfurt am Main, Frankfurt, Germany On behalf of TRAMI registry

Funding Acknowledgement: Type of funding source: Private grant(s) and/or Sponsorship. Main funding source(s): The TRAMI registry has been supported by proprietary means of IHF. Additional funding is provided by "Deutsche Herzstiftung" and a grant from Abbott Vascular.

Background: Left atrium (LA) dimension is a marker of disease severity and outcome in primary and secondary mitral regurgitation. In transcatheter mitral valve repair LA enlargement might additionally impact on device handling and technical success through an altered anatomy and atrial annular dilatation.

Methods: Data from the multicenter German transcatheter mitral valve intervention registry "TRAMI" were used to analyse the association of baseline LA diameter by tertiles and efficacy, safety and long-term clinical outcome in patients undergoing edge-to-edge repair with the MitraClip.

Results: In 520 of 843 patients prospectively enrolled in TRAMI baseline LA diameter were reported (median [interquartile range] LA diameter in tertiles: 44 [40–46] mm, 51 [48–53] mm and 60 [55–66] mm). Larger LA diameters were significantly associated with secondary etiology of mitral re-

gurgitation, lower ejection fraction, larger left ventricle, male sex and atrial fibrillation (all p<0.05). Technical success was not different across tertiles (96%, 95.4%, 98.4% respectively, p=0.43) as were major in-hospital cardiovascular and cerebral adverse events (mortality, myocardial infarction or stroke) (1.8%, 1.2% and 4.4%, p=0.11 across tertiles). However, 4-year mortality significantly increased with larger LA diameter (32.9%, 46.4% and 51.7% respectively, p<0.01), as did hospitalization in survivors (60%, 67.6% and 78.9% respectively, p<0.05). The association between LA diameter and all-cause mortality remained significant after multivariable adjustment including baseline left ventricular end-diastolic diameter.

Conclusion: LA enlargement is a strong and independent predictor of adverse long-term outcome in mitral regurgitation suggesting that timely transcatheter mitral valve repair may have the potential to modify outcome.